Piper Sandler Maintains Overweight on Akebia Therapeutics, Lowers Price Target to $2
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:AKBA) with a Overweight and lowers the price target from $4 to $2.
Piper Sandler analyst Allison Bratzel maintains Akebia Therapeutics (NASDAQ:AKBA) with a Overweight and lowers the price target from $4 to $2.
